Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | February 13, 2014 |
| Target | 4-Antibody AG |
| Sector | Life Science |
| Buyer(s) | Agenus |
| Deal Type | Add-on Acquisition |
| Deal Value | 40M USD |
| Advisor(s) | Torreya Partners (Financial) |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Life Science |
| Employees | 389 |
| Revenue | 103M USD (2024) |
Agenus is a biotechnology company developing treatments for cancers and infectious diseases. Agenus was incorporated in 1994 and is based in Lexington, Massachusetts.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Life Science | 1 of 3 |
| Type: Add-on Acquisition | 1 of 2 |
| Country: Switzerland | 1 of 1 |
| Year: 2014 | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-04-08 |
Celexion - Key Antibody Assets
Cambridge, Massachusetts, United States Celexion's Key Antibody Assets is a SECANT yeast display platform for the generation of novel monoclonal antibodies. SECANT is designed to enable highly efficient interrogation of drug targets such as checkpoint proteins. |
Buy | $4M |
